Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.59 |
| ▸ | FYN | P06241 | 3/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | LDHB | P07195 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18286643 | 0.92 | CSF1R (0.60) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL5208271 | 0.91 | FYN (0.67) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL5934776 | 0.91 | FYN (0.67) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL5205798 | 0.90 | CSF1R (0.65) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL5208442 | 0.90 | CSF1R (0.65) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL12104596 | 0.87 | CSF1R (0.66) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL5208910 | 0.85 | CSF1R (0.67) | CSF1RFYNLDHALDHBCCNT1 | |
| SCHEMBL12056840 | 0.85 | CCNC (0.50) | CSF1RFYNCCNT1CDK9CCNC | |
| SCHEMBL12056823 | 0.85 | CCNC (0.50) | CSF1RFYNCCNT1CDK9CCNC | |
| SCHEMBL18286638 | 0.85 | CCNC (0.50) | CSF1RFYNCCNT1CDK9CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | CSF1R 1399/4885FYN 498/4885LDHA 3998/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | CSF1R 3034/4885FYN 359/4885LDHA 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.